Encontrados 10 documentos, a visualizar página 1 de 1
Disparities in the organisation of national healthcare systems for treatment of...
Michelsen, Brigitte; Østergaard, Mikkel; Nissen, Michael John; Ciurea, Adrian; Möller, Burkhard; Midtbøll Ørnbjerg, Lykke; Horák, PavelFunding Information: The EuroSpA Research Collaboration Network was financially supported by Novartis Pharma AG. Novartis had no influence on the data collection, analyses, manuscript preparation or decision to submit the manuscript. Publisher Copyright: © 2025; Background: Studies on national policies for biologics are warranted. Objectives: To map and compare national healthcare set-ups for prescription, star...
Predictors of Secukinumab Treatment Response and Continuation in Axial Spondylo...
Pons, Marion; Georgiadis, Stylianos; Hetland, Merete Lund; Ahmadzay, Zohra Faizy; Rasmussen, Simon; Christiansen, Sara N.; Di Giuseppe, DanielaPublisher Copyright: © 2025 The Journal of Rheumatology.; Objective. In patients with axial spondyloarthritis (axSpA) initiating secukinumab (SEC), we aimed to identify baseline (treatment start) predictors of achieving low disease activity (LDA) after 6 months, as measured by the Axial Spondyloarthritis Disease Activity Score using C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity...
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Ar...
Aymon, Romain; Mongin, Denis; Guemara, Romain; Salis, Zubeyir; Askling, Johan; Choquette, Denis; Codreanu, Catalin; Di Giuseppe, Daniela; Flouri, IriniFunding Information: Supported by AbbVie, Galapagos, Pfizer, and Eli Lilly. Publisher Copyright: © 2025 The Author(s). Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.; Objective: Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor ne...
Differences in the response to TNF inhibitors at distinct joint locations in pa...
Ciurea, Adrian; Kissling, Seraphina; Götschi, Andrea; Ørnbjerg, Lykke Midtbøll; Rasmussen, Simon Horskjær; Tamási, Bálint; Möller, BurkhardPublisher Copyright: © The Author(s) 2025.; Background: Efficacy of tumour necrosis factor inhibitors (TNFi) for peripheral arthritis in patients with psoriatic arthritis (PsA) has been established in randomized clinical trials that have used improvement in summated joint counts as an outcome. Whether joints at different anatomical locations might respond differentially to TNFi remains unknown. The aim of the s...
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis
Ørnbjerg, Lykke Midtbøll; Brahe, Cecilie Heegaard; Linde, Louise; Jacobsson, Lennart; Nissen, Michael J.; Kristianslund, Eirik Klami; Santos, Maria JoséFunding Information: This work was supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit. Publisher Copyright: © 2024 The Authors; Objective: To investigate real-world retention and remission rates in PsA patients initiating a 2nd or 3rd TNFi and the association with reason for discontinuation from the previous TNFi-treatment....
Recording of non-musculoskeletal manifestations, comorbidities and safety outco...
Ahmadzay, Zohra F.; Heberg, Jette; Jørgensen, Jacob B.; Ørnbjerg, Lykke M.; Østergaard, Mikkel; Møller-Bisgaard, Signe; Michelsen, BrigitteFunding Information: This work was supported by Novartis Pharma AG. EuroSpA was financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit the manuscript. Publisher Copyright: © 2024 The Author(s).; Objectives: Real-world evidence is needed to inform treatment strategies for patients with PsA and axial SpA (axSpA) who h...
Impact of patient characteristics on ASDAS disease activity state cut-offs in a...
Ørnbjerg, Lykke M.; Georgiadis, Stylianos; Kvien, Tore K.; Michelsen, Brigitte; Rasmussen, Simon; Pavelka, Karel; Zavada, Jakub; Loft, Anne GittePublisher Copyright: © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.; OBJECTIVES: To re-evaluate cut-offs for disease activity states according to the Axial Spondyloarthritis Disease Activity Score (ASDAS), and study the impact of sex, age, calendar time, disease and symptom duration on ASDAS and ASDAS cut-offs in a la...
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyl...
Christiansen, Sara Nysom; Rasmussen, Simon Horskjær; Ostergaard, Mikkel; Pons, Marion; Michelsen, Brigitte; Pavelka, Karel; Codreanu, CatalinFunding Information: Novartis Pharma AG for supporting the EuroSpA collaboration. The paper has been presented at the Scandinavia Congress of Rheumatology 2023 as an oral presentation and at the EULAR 2023 Congress as a poster presentation (POS0656) with the following abstract: SNC, SHR, LMO, etc. Does radiographic status impact secukinumab effectiveness in European axial spondyloarthritis patients treated in r...
Corrigendum to ‘Predictors of ASDAS-CRP inactive disease in axial spondyloarthr...
Ørnbjerg, Lykke M.; Linde, Louise; Georgiadis, Stylianos; Rasmussen, Simon H.; Lindström, Ulf; Askling, Johan; Michelsen, Brigitte; Giuseppe, Daniela DiThe authors regret that the following incorrect values have been published in the original paper: In the abstract: Line 11-12: “age, per year: 0.97 (0.97-0.98)” should be “age, per year: 0.98 (0.97-0.99)” Line 12: “men vs. women: 1.88 (1.60-2.22)” should be “men vs. women: 1.79 (1.51-2.12)” Line 12: “current vs. non-smoking: 0.76 (0.63-0.91)” should be “current vs. non-smoking: 0.72 (0.59-0.87)” Line 12-13: “HL...
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during trea...
Ørnbjerg, Lykke M.; Linde, Louise; Georgiadis, Stylianos; Rasmussen, Simon H.; Lindström, Ulf; Askling, Johan; Michelsen, Brigitte; Giuseppe, Daniela DiFunding Information: LMØ, LL, SG and SHR: research grants from Novartis; UL: none; DDG none; JKW: consultant of AbbVie, Amgen, Celgene, Eli Lilly and Novartis; BG: research grants from Pfizer, Abbvie and BMS; LP: consultant of Novartis Finland, UCB Pharma, Pfizer, Sanofi, BMS, AbbVie, Amgen, Celgene, Eli Lilly, Boehringer-Ingelheim, Mylan; KL: consulting and/or speaking fees from Amgen, Johnson and Johnson and ...